Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Detection of Tumor-Associated Autoantibodies in the Sera of Pancreatic Cancer Patients Using Engineered MUC1 Glycopeptide Nanoparticle Probes

  • Corzana, Francisco
  • Asín, Alicia
  • Eguskiza, Ander
  • De Tomi, Elisa
  • Martín-Carnicero, Alfonso
  • Martínez-Moral, María P.
  • Mangini, Vincenzo
  • Papi, Francesco
  • Bretón, Carmen
  • Oroz, Paula
  • Lagartera, Laura
  • Jiménez-Moreno, Ester
  • Avenoza, Alberto
  • Busto, Jesús H.
  • Nativi, Cristina
  • Asensio, Juan Luis
  • Hurtado-Guerrero, Ramón
  • Peregrina, Jesús M.
  • Malerba, Giovanni
  • Martínez, Alfredo
  • Fiammengo, Roberto
Pancreatic cancer is one of the deadliest cancers worldwide, mainly due to late diagnosis. Therefore, there is an urgent need for novel diagnostic approaches to identify the disease as early as possible. We have developed a diagnostic assay for pancreatic cancer based on the detection of naturally occurring tumor associated autoantibodies against Mucin-1 (MUC1) using engineered glycopeptides on nanoparticle probes. We used a structure-guided approach to develop unnatural glycopeptides as model antigens for tumor-associated MUC1. We designed a collection of 13 glycopeptides to bind either SM3 or 5E5, two monoclonal antibodies with distinct epitopes known to recognize tumor associated MUC1. Glycopeptide binding to SM3 or 5E5 was confirmed by surface plasmon resonance and rationalized by molecular dynamics simulations. These model antigens were conjugated to gold nanoparticles and used in a dot-blot assay to detect autoantibodies in serum samples from pancreatic cancer patients and healthy volunteers. Nanoparticle probes with glycopeptides displaying the SM3 epitope did not have diagnostic potential. Instead, nanoparticle probes displaying glycopeptides with high affinity for 5E5 could discriminate between cancer patients and healthy controls. Remarkably, the best-discriminating probes show significantly better true and false positive rates than the current clinical biomarkers CA19-9 and carcinoembryonic antigen (CEA)., This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No956544. We thank Dr. Sara Gasperini of the General Pathology Section, Department of Medicine, University of Verona, for providing access and assistance with the LI–COR Odyssey Infrared Imaging System. We thank Prof.Henrik Clausen from Copenhagen Center for Glycomics atUniversity of Copenhagen for his insightful comments. F.C.thanks the Mizutani Foundation for Glycoscience (grant220115) and AECC (INNOVA 2023 project). A.A. and C.B.thank the Asociación Española Contra el Cáncer (AECC),sección La Rioja, for their doctoral fellow ships. We thank the ALBA (Barcelona, Spain) synchrotron beamline XA-LOC. We thank ARAID, the Agencia Estatal de Investiga-ción (AEI, BFU201675633-P, PID2019-105451GB-I00, and PID2022-136362NB-I00 to R.H.-G., PID2022-136735OB-I00to A.M., PID2021-127030OA-I00 to E.J.-M, PID2022-141085NB-100 to J.L.A, and PID2021-127622OB-I00 andPDC2022-133725-C21 to F.C. and J.H.B.), Universidad de La Rioja (REGI22/47 and REGI22/16), Gobierno de Aragón (E34_R17 and LMP58_18 to R.H.-G.) with FEDER(2014–2020) funds for “Building Europe from Aragón” forfinancial support, and the COST Action CA18103 INNO-GLY: Innovation with Glycans new frontiers from synthesis to new biological targets. CN thanks Fondazione AIRC,project IG25762. Open Access publishing facilitated byUniversità degli Studi di Verona, as part of the Wiley -CRUI-CARE agreement., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Rational design of dual-domain binding inhibitors for N-acetylgalactosamine transferase 2 with improved selectivity over the T1 and T3 isoforms

  • Compañón, Ismael
  • Ballard, Collin J.
  • Lira-Navarrete, Erandi
  • Santos, Tanausú
  • Monaco, Serena
  • Muñoz-García, Juan C.
  • Delso, J. Ignacio
  • Angulo, Jesús
  • Gerken, Thomas A.
  • Schjoldager, Katrine T.
  • Clausen, Henrik
  • Tejero, Tomás
  • Merino, Pedro
  • Corzana, Francisco
  • Hurtado-Guerrero, Ramón
  • Ghirardello, Mattia
The GalNAc-transferase (GalNAc-T) family, consisting of 20 isoenzymes, regulates the O-glycosylation process of mucin glycopeptides by transferring GalNAc units to serine/threonine residues. Dysregulation of specific GalNAc-Ts is associated with various diseases, making these enzymes attractive targets for drug development. The development of inhibitors is key to understanding the implications of GalNAc-Ts in human diseases. However, developing selective inhibitors for individual GalNAc-Ts represents a major challenge due to shared structural similarities among the isoenzymes and some degree of redundancy among the natural substrates. Herein, we report the development of a GalNAc-T2 inhibitor with higher potency compared to those of the T1 and T3 isoforms. The most promising candidate features bivalent GalNAc and thiophene moieties on a peptide chain, enabling binding to both the lectin and catalytic domains of the enzyme. The binding mode was confirmed by competitive saturation transfer difference NMR experiments and validated through molecular dynamics simulations. The inhibitor demonstrated an IC50 of 21.4 μM for GalNAc-T2, with 8- and 32-fold higher selectivity over the T3 and T1 isoforms, respectively, representing a significant step forward in the synthesis of specific GalNAc-T inhibitors tailored to the unique structural features of the targeted isoform., We thank the Agencia Estatal de Investigación (AEI, PID2021-127622OB-I00 and PDC2022-133725-C21 to F.C., PID2022-136362NB-I00 to R.H.-G., PID2022137973NB-I00 to P.M.), Universidad de La Rioja (REGI22/16 Project), and Gobierno de Aragón (E34_R17 and LMP58_18) with FEDER (2014–2020) funds for ‘Building Europe from Aragón’ for financial support (to R.H.-G.). The support of the National Institutes of Health grant R01-GM113535 (to T.A.G.) is also acknowledged. M.G. and I.D. acknowledge the Marie Skłodowska-Curie fellowship program (grant agreement nos. 101034288 (M.G.) and 890779 (I.D.)) for financial support. J.A. and S.M. acknowledge support of BBSRC, grant BB/P010660/1. J.A. and J.C.M.-G. also acknowledge funding from the grant AEI/10.13039/501100011033/PID2022-142879NB-I00, cofunded by the European Regional Development Fund (ERDF), “A way of making Europe”, and T.S. thanks MICIU/AEI /10.13039/501100011033 and the European Union NextGenerationEU/PRTR for his Juan de la Cierva contract, JDC2022-048607-I., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Exploring photoredox catalytic reactions as an entry to glycosyl-α-amino acids

  • Bretón, Carmen
  • Oroz, Paula
  • Torres, Miguel
  • Zurbano, María M.
  • García-Orduña, Pilar
  • Avenoza, Alberto
  • Busto, Jesús H.
  • Corzana, Francisco
  • Peregrina, Jesús M.
The synthesis of glycosyl-α-amino acids presents a significant challenge due to the need for precise glycosidic linkages connecting carbohydrate moieties to amino acids while maintaining stereo- and regiochemical fidelity. Classical methods relying on ionic intermediates (2e–) often involve intricate synthetic procedures, particularly when dealing with 2-N-acetamido-2-deoxyglycosides linked to α-amino acids—a crucial class of glycoconjugates that play important biological roles. Considering the growing prominence of photocatalysis, this study explores various photoredox catalytic approaches to achieving glycosylation reactions. Our focus lies on the notoriously difficult case of 2-N-acetamido-2-deoxyglycosyl-α-amino acids, which could be obtained efficiently by two methodologies that involved, on the one hand, photoredox Giese reactions using a chiral dehydroalanine (Dha) as an electron density-deficient alkene in these radical 1,4-additions and, on the other hand, photoredox glycosylations using selenoglycosides as glycosyl donors and hydroxyl groups of protected amino acids as acceptors., We thank the Agencia Estatal de Investigación of Spain (AEI; PID2021-127622OB-I00 and PDC2022-133725-C21 projects), the Asociación Española Contra el Cáncer (AECC, INNOVA project 2023), Universidad de La Rioja (REGI22/47 and REGI22/16 projects), and the EU (Marie-Sklodowska Curie ITN, DIRNANO, grant agreement No. 956544). C.B. and M.T. thank (AECC La Rioja) for predoctoral fellowships., Peer reviewed
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Exploring Photoredox Catalytic Reactions as an Entry to Glycosyl-a-amino Acids

  • Bretón, Carmen
  • Oroz, Paula
  • Torres, Miguel
  • Zurbano, María M.
  • García-Orduña, Pilar
  • Avenoza, Alberto
  • Busto, Jesús H.
  • Corzana, Francisco
  • Peregrina, Jesús M.
The synthesis of glycosyl-α-amino acids presents a significant challenge due to the need for precise glycosidic linkages connecting carbohydrate moieties to amino acids while maintaining stereo- and regiochemical fidelity. Classical methods relying on ionic intermediates (2e–) often involve intricate synthetic procedures, particularly when dealing with 2-N-acetamido-2-deoxyglycosides linked to α-amino acids─a crucial class of glycoconjugates that play important biological roles. Considering the growing prominence of photocatalysis, this study explores various photoredox catalytic approaches to achieving glycosylation reactions. Our focus lies on the notoriously difficult case of 2-N-acetamido-2-deoxyglycosyl-α-amino acids, which could be obtained efficiently by two methodologies that involved, on the one hand, photoredox Giese reactions using a chiral dehydroalanine (Dha) as an electron density-deficient alkene in these radical 1,4-additions and, on the other hand, photoredox glycosylations using selenoglycosides as glycosyl donors and hydroxyl groups of protected amino acids as acceptors.